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Letter to the Editor 
Cytomegalovirus infection in patients undergoing autologous 
peripheral blood stem cell transplantation 
Massimo Franchin& Sergio Pizzighella,(2) Aurora Vassanelli,@) Paolo Rocca,(l) Vittorio Meneghini,(l) 
Dino Veneri,(l) Giuseppe Lippic3) and Fabio Benedetticl) 
Cytomegalovirus (CMV) infection is a well known 
cause of morbidity and mortality in patients under- 
going allogeneic bone marrow transplantation (BMT) 
management. Although many clinical trials have been 
carried out worldwide on this topic,l little is known 
about the role of CMV infection after autologous BMT 
(ABMT).2-s 
In this study, the incidence and the clinical 
characteristics of CMV infection were evaluated in 40 
consecutive patients (29 male and 11 female; mean age 
40 y, range 28-59 y) affected by hematologic malignan- 
cies. The subjects were enrolled between January 1995 
and December 1998 in a sequential high-dose chemo- 
therapy program with peripheral blood stem cell 
(PBSC) rescue. Twenty-two patients had non-Hodgkin’s 
lymphoma, twelve had Hodgkin’s disease, and six 
had multiple myeloma. The high-dose chemotherapy 
regimen included cyclophosphamide 7000 mg/m2 intra- 
venously (IV) on day -48 followed by granulocyte- 
macrophage colony-stimulating factor (GM-CSF) 
Table 1. Summary of Clinical and Therapeutic Data 
5 pg/kg IV once daily until PBSC collection. Metho- 
trexate 8000 mg/m2 IV with leucovorin rescue and 
vincristine 1.4 mg/m2 IV were given on day -28. Etopo- 
side 2000 mg/m2 IV was given on day -20 followed 
by granulocyte colony-stimulating factor (G-CSF) 
(5 yg/kg/d IV) starting on day -19 until the absolute 
neutrophil count was above 0.5 x 109/L for 3 consecutive 
days. Patients received melphalan (140 mg/m2 IV) and 
mitoxantrone (60 mg/m2 IV) on day -2 and PBSC 
were infused on day 0. Granulocyte CSF (5 pg/kg/IV 
once daily) was given starting on day +l until the 
absolute neutrophil count was above 0.5x109/L for 3 
consecutive days. Thirty-three of 40 patients (82.5%) 
were CMV positive (IgG+, IgM-) at the time of trans- 
plantation. All patients enrolled were tested weekly for 
CMV pp65 antigenemia, with shell vials and long-term 
cultures starting before the chemotherapy regimen and 
continuing until the patient was discharged. Twenty- 
three patients (57.5%) received CMV prophylaxis with 
acyclovir 10 mg/kg IV three times a day starting on day 
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HD=Hodgkin’s disease; NHL=non-Hodgkin’s lymphoma; MM=multiple myeloma; CMV=cytomegalovirus; ABMT=autologous bone 
marrow transplantation; SV=shell vial; LTC=long-term culture; -=negative; +=positive. 
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-5 through day +30 after transplantion. Cytomegalo- 
virus infection developed in 11 of 40 patients (27.5%), 
all but one without CMV prophylaxis. Nine of eleven 
patients (81.8%) were CMV IgG positive (CMV reacti- 
vation), two (18.2%) were CMV IgG negative (primary 
infection). In all 11 cases, infection was defined by an 
antigenemia-positive test. Positive shell vials and long- 
term cultures from blood were detected in five of 
eleven patients (45.4%). Positive cultures from urine 
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were detected in seven of eleven patients (63.6%): 
viruria without viremia was noted in two cases (patients 
5 and 6). In most cases, infection occurred just prior to 
autologous PBSC transplantation (average time, 3 d 
before transplantation; range -21 d pre-BMT, +20 d 
post-BMT). The patients’ characteristics, the CMV 
status at transplantation, the CMV monitoring, and the 
therapeutic data are summarized in Table 1. In all cases, 
CMV infection was only a laboratory finding and none 
of the patients had clinical symptoms. Treatment with 
acyclovir 15 mg/kg IV three times a day rapidly 
resolved the infection in seven of eleven patients, 
whereas four patients (all without prophylaxis) 
required further therapy with ganciclovir or foscarnet. 
The data show that patients undergoing high-dose 
chemotherapy regimens may be at risk for CMV reacti- 
vation. Although CMV reactivation was only a labor- 
atory finding in these patients undergoing autologous 
PBSC transplantation, this report underlines the need 
for close monitoring for CMV following BMT. 
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